Abstract:OBJECTIVES:Highly active antiretroviral therapy (HAART) has being impacted significantly therapies for natural human immunodeficiency virus (HIV) infection, which leads to a remarkable decrease in its morbidity and mortality but it is frequently associated with metabolic complications such as dyslipidaemia and cardiovascular complications. HIV reverse transcriptase (RT) inhibitors can be classified into nucleoside and non-nucleoside types. Mitochondrial dysfunction due to the depletion of mt-DNA is partly responsible for various nucleoside RT inhibitors-associated adverse effects including dyslipidaemia. Efavirenz (EFV) is metabolized primarily by cytochrome P450 2B6 (CYP2B6) and the metabolic effects of EFV have been described previously. All patients in this study received the same HAART treatment regime (Stavudine (d4T) + Lamivudine (3TC) + Efavirenz (EFV)). This study aims to assess incidences for dyslipidaemia and atherosclerosis. METHODS:This retrospective study was conducted within outpatients of Shanghai Public Health Center. We selected thirty-five HIV-1 infected patients who receiving highly active antiretroviral therapy. Their mean CD4 cell count was 69.5 (±34.6) copies per micro liter before therapy. Fasting total cholesterol, triglyceride, high-density lipoprotein (HDL) cholesterol and low-density lipoprotein (LDL) cholesterol values were respectively compared among patients at present and before therapy. Then the data was statistically analyzed. Twenty-two patients had the intima-media thickness (IMT) of their carotid arteries measured by Philips 5000 Color-Doppler ultrasound tests. RESULTS:After therapy, patients achieved significant changes in levels of triglycerides (1.44 ± 0.35mmol/L Vs. 2.07 ± 0.54mmol/L) (P<0.001), total cholesterol (4.96 ± 0.46 mmol/L Vs. 6.15 ± 0.83mmol/L) (P<0.001) and LDL cholesterol (2.29 ± 0.33 Vs. 3.11 ± 0.29 mmol/L) (P<0.001). In contrast, the level of HDL cholesterol did not significantly change (1.06 ± 0.01 mmol/L Vs. 1.04 ± 0.01 mmol/L) (P>0.5). The mean IMT of twenty-two patients was (0.86 ± 0.14) mm after HAART, which is higher than the norm age-matched value of (0.7 ± 0.2) mm (P<0.05). RESULTS:After therapy, patients achieved significant changes in levels of triglycerides (1.44 ± 0.35mmol/L Vs. 2.07 ± 0.54mmol/L) (P<0.001), total cholesterol (4.96 ± 0.46 mmol/L Vs. 6.15 ± 0.83mmol/L) (P<0.001) and LDL cholesterol (2.29 ± 0.33 Vs. 3.11 ± 0.29 mmol/L) (P<0.001). In contrast, the level of HDL cholesterol did not significantly change (1.06 ± 0.01 mmol/L Vs. 1.04 ± 0.01 mmol/L) (P>0.5). The mean IMT of twenty-two patients was (0.86 ± 0.14) mm after HAART, which is higher than the norm age-matched value of (0.7 ± 0.2) mm (P<0.05). CONCLUSION:These data suggest that HAART is potentially dangerous for hyperlipidaemia and maybe an increase in atherosclerosis.

Clinical study of hyperlipidemia and fatty liver disease in patients receiving HAART

[Highly Active Antiretroviral Therapy on Liver Function in HIV-positive Children with HBV/HCV Co-Infection].

The effect of different HAART regimens on liver function and HIV load of HIV infected children with HCV co-infection

The Impact of Highly Active Antiretroviral Treatment on the Blood Profiles of Patients with Acquired Immune Deficiency Syndrome

Severe Dyslipidemia and Immune Activation in HIV Patients with Dysglycemia

Dyslipidaemia and Intima-Media Thickness of Carotid Arteries in Thirty-Five HIV/AIDS Patients Receiving Highly Active Antiretroviral Therapy

The Effect of Highly Active Antiretroviral Therapy on Liver Function in Human Immunodeficiency Virus-Infected Pediatric Patients with or Without Hepatitis Virus Co-Infection

Association of serum lipid profile with liver fibrosis in HCV‑coinfected HIV patients on suppressive anti‑retroviral therapy

Biological characteristics and survival analysis in HIV/HCV co-infected patients

Changes in Lipid Indices in HIV+ Cases on HAART.

Liver fibrosis after antiretroviral therapy in a longitudinal cohort of sexually infected HIV patients in eastern China.

The risk of dyslipidemia on PLHIV associated with different antiretroviral regimens in Huzhou

A study on lipids and C-reactive protein in HIV-infected patients

Efficacy and safety of efavirenz-based regimens in human immunodeficiency virus/hepatitis C virus co-infected patients

Efficacy analysis of HAART in 52 cases o hemophilia with HIV/HCV coinfection

Four years clinical analysis of 50 cases of hemophilia patients co-infected by AIDS/HCV treated with active antiretroviral therapy

Efficacy Analysis of HAART in 52 Cases of Hemophilia with HIV/HCV Coinfection

Association Between Hepatic Steatosis And Entecavir Treatment Failure In Chinese Patients With Chronic Hepatitis B

The change of carotid intima-media thickness in HIV/AIDS patients after highly active antiretroviral therapy

Liver triglyceride content in HIV-1-infected patients on combination antiretroviral therapy studied with 1H-MR spectroscopy

OL-005 A Higher Correlation of HCV Core Antigen with CD4+ T Cell Counts in HCV/HIV Coinfected Patients